Factors predicting long-term efficacy of Hylan GF-20 viscosupplementation in knee osteoarthritis

Conrozier, Thierry; Mathieu, Pierre; Schott, Anne-Marie; Laurent, Isabelle; Hajri, Touria; Crozes, Pierre; Grand, P.; H, Laurent; Marchand, François; Meignan, F.; Noël, É.; Rozand, Yves; Savoye, Jean-François; Vignon, E.

doi:10.1016/s1297-319x(03)00005-8

Cited by 61 publications

(43 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Knee joint space loss in a single compartment seen on radiograph and meniscal calcinosis noted on MRI scans were predictive of good outcome to knee IA Hylan GF-20. The definition of treatment responder was not adequately described in this retrospective cohort, so it is difficult to define the improvement that is actually predicted by these measures (24).Nevertheless, weak evidence exists that knee These outcomes were all found to be significantly improved at 12 weeks but the responder criteria were not specified. Seven possible predictors of reduced pain and improved functional ability were analysed using regression modelling.…”

Section: Radiographic and Mri Assessmentmentioning

confidence: 93%

“…Longer term outcomes of patients with knee OA receiving IA Hylan G-F were explored in the following three cohort studies (24)(25)(26). A retrospective cohort of 155 patients with knee OA was reassessed 7-14 months following IA Hylan G-F 20 (24).…”

Section: Body Mass Indexmentioning

confidence: 99%

“…A retrospective cohort of 155 patients with knee OA was reassessed 7-14 months following IA Hylan G-F 20 (24). The definition of responder was not specified.…”

Section: Body Mass Indexmentioning

confidence: 99%

“…The evidence is weak that BMI is not predictive of treatment response to either a multi-modal stepped-care pain management model (18,19), hip CSI (22) hip IA Hylan G-F20 (27), or glucosamine for chronic knee pain (28). The evidence for BMI as a predictor of response to knee IA Hylan G-F is weak and conflicting (23)(24)(25)(26). Further research is required to determine whether BMI is a clinical characteristic that can foretell response to non-surgical treatments for people with hip and knee OA.…”

Section: Body Mass Indexmentioning

confidence: 99%

“…Three cohort studies attempted to identify radiographic characteristics of patients with hip and knee OA that were predictive of treatment response to IA Hylan G-F 20 (24,25,27). Migliore et al (2008) followed 250 patients who received US-guided IA hylan G-F 20 into OA hips (27).…”

Section: Radiographic and Mri Assessmentmentioning

confidence: 99%

See 4 more Smart Citations

Targeting Care

Eyles

Lucas

Hunter

2013

Rheumatic Disease Clinics of North America

View full text Add to dashboard Cite

Important points and objectives for recall:• Numerous studies have explored patient characteristics including: body mass index, psychological factors, muscle strength, tibiofemoral alignment, radiographic changes and signs of inflammation as potential predictors of response to non-surgical interventions for management of hip and knee OA.• Often the sample sizes utilized by these studies were inadequate to yield sufficient numbers of responders to the interventions to allow for analysis of the potential predictors identified.• A number of well-designed studies were adequately powered to provide some evidence for clinical characteristics that did or did not predict response to non-surgical interventions for participants with hip and knee OA. SynopsisInternational evidence-based guidelines recommend a multitude of non-surgical treatment options for the management of OA. In the face of so many choices, it would be helpful for clinicians to be able to base treatment decisions on the identification of specific clinical presentations that foretell greater likelihood of success following a given treatment. This review summarizes the evidence available for patient characteristics that have been analysed as potential predictors of response to non-surgical interventions for patients with hip and knee OA. The specific variables targeted for this review include: body mass index, psychological factors, muscle strength, tibiofemoral alignment, radiographic changes and signs of inflammation. Several studies provide moderate to good evidence of potential predictors of response to non-surgical treatments, while areas for future research are illuminated.

show abstract

Section: Radiographic and Mri Assessmentmentioning

confidence: 93%

Section: Body Mass Indexmentioning

confidence: 99%

“…A retrospective cohort of 155 patients with knee OA was reassessed 7-14 months following IA Hylan G-F 20 (24). The definition of responder was not specified.…”

Section: Body Mass Indexmentioning

confidence: 99%

Section: Body Mass Indexmentioning

confidence: 99%

Section: Radiographic and Mri Assessmentmentioning

confidence: 99%

See 3 more Smart Citations

Targeting Care

Eyles

Lucas

Hunter

2013

Rheumatic Disease Clinics of North America

View full text Add to dashboard Cite

show abstract

Early effect of hyaluronic acid intra‐articular injections on serum and urine biomarkers in patients with knee osteoarthritis: An open‐label observational prospective study

Conrozier

Balblanc

Richette

et al. 2011

Journal Orthopaedic Research

Self Cite

View full text Add to dashboard Cite

The aim of the study was to investigate the effect of hyaluronic acid (HA) intra articular injections (IA) on osteoarthritis (OA) biomarkers in patients with knee OA. Prospective open label study. Fifty-one patients with unilateral symptomatic K-OA received IA injections of 2mL of HA on days (D) 1, 7, 14 and were followed 3 months. At D-15 patients were examined and X-rays performed, to exclude patients with bilateral K-OA, or those with more than three symptomatic OA joints. From 15 days (D-15) before the first injection to D90 concomitant therapies were unchanged. Walking pain (WP) on VAS was obtained at each visit. Urine (U) and serum (S) samples were obtained at D-15, D1, D30, and D90. S-C2C, S-Cartilage oligomeric matrix protein, S-HA, S-CS 846 epitope, S-type II collagen propeptide, and U-type II collagen C telopeptide (U-CTX II/creatinin) were assayed. Predictive factors of response were analyzed using logistic regression. Correlations between variables were obtained using Spearman test. Forty-five patients were analyzed. Between D-15 and D1 there was no difference for any biomarkers At D1, WP (SD) was correlated with U-CTX II/creat (p ¼ 0.006). Between D1 and D90: U-CTX II/creat decreased significantly. After adjustment for confounding variables there was a significant correlation between clinical response and U-CTX II/creat variation. U-CTX II and S-HA at baseline were independently predictive of clinical response. This study showed that 90 days after HA IA injections, U-CTX II levels significantly decrease compared to baseline, suggesting a slowdown of type II collagen degradation. ß

show abstract

Early decrease of serum biomarkers of type II collagen degradation (Coll2‐1) and joint inflammation (Coll2‐1 NO₂) by hyaluronic acid intra‐articular injections in patients with knee osteoarthritis: A research study part of the Biovisco study

Henrotin

Chevalier²,

Deberg³

et al. 2013

Journal Orthopaedic Research

View full text Add to dashboard Cite

To measure the evolution of the serum levels of specific Osteoarthritis (OA) biomarker, Coll2-1 and Coll2-1 NO 2 in knee osteoarthritic patients after viscosupplementation (VS). Fifty-one patients with unilateral symptomatic knee were recruited for this prospective open label study. They received three intra-articular injections of 2 ml of hyaluronic acid (Hylan GF-20) and were followed for 3 months. Walking pain was evaluated and serum samples were taken at each visit. Coll2-1 and Coll2-1 NO 2 were measured in the serum using specific immunoassays. Variations over time of each parameter and predictive factor of response were studied. Forty-five patients were analyzed. The serum concentrations of Coll2-1 and Coll2-1 NO 2 were significantly higher in KL III/IV patients compared to KL I/II patients at baseline and decreased systematically over time after VS. Its effect was ever more pronounced in patients with KL III/IV. The serum concentration of Coll2-1 was significantly lower at baseline in responders than in non-responders. This study suggests a rapid slowdown of type II collagen degradation and joint inflammation after VS with Hylan G-20 and gives additional information for the validation of accurate biomarkers for OA. The serum level of Coll2-1 appeared to be a predictive factor for response to treatment. ß

show abstract

Factors predicting long-term efficacy of Hylan GF-20 viscosupplementation in knee osteoarthritis

Cited by 61 publications

References 9 publications

Targeting Care

Targeting Care

Early effect of hyaluronic acid intra‐articular injections on serum and urine biomarkers in patients with knee osteoarthritis: An open‐label observational prospective study

Early decrease of serum biomarkers of type II collagen degradation (Coll2‐1) and joint inflammation (Coll2‐1 NO₂) by hyaluronic acid intra‐articular injections in patients with knee osteoarthritis: A research study part of the Biovisco study

Contact Info

Product

Resources

About

Factors predicting long-term efficacy of Hylan GF-20 viscosupplementation in knee osteoarthritis

Cited by 61 publications

References 9 publications

Targeting Care

Targeting Care

Early effect of hyaluronic acid intra‐articular injections on serum and urine biomarkers in patients with knee osteoarthritis: An open‐label observational prospective study

Early decrease of serum biomarkers of type II collagen degradation (Coll2‐1) and joint inflammation (Coll2‐1 NO2) by hyaluronic acid intra‐articular injections in patients with knee osteoarthritis: A research study part of the Biovisco study

Contact Info

Product

Resources

About

Early decrease of serum biomarkers of type II collagen degradation (Coll2‐1) and joint inflammation (Coll2‐1 NO₂) by hyaluronic acid intra‐articular injections in patients with knee osteoarthritis: A research study part of the Biovisco study